Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Blad-Care is a medical device and therapeutic solution developed by BioPlus for the treatment of bladder inflammation and the improvement of cystitis symptoms. It is composed of sodium hyaluronate and sodium chondroitin sulfate, which are the primary components of the glycosaminoglycan (GAG) layer that coats and protects the bladder epithelium. In patients with conditions such as interstitial cystitis, radiation-induced cystitis, or chronic recurrent cystitis, the GAG layer is often deficient or damaged, allowing toxic urinary solutes to penetrate the bladder wall and trigger pain, urgency, and inflammation. Blad-Care is administered via intravesical instillation, where it acts as a biocompatible biomaterial to replenish the protective GAG layer, restore the integrity of the mucosal barrier, and shield the underlying tissues. Approved in South Korea in 2021, it is used as a tissue repair material and a supportive treatment for various forms of bladder wall damage.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Blad-Care.